SiBone (SIBN)
(Delayed Data from NSDQ)
$16.55 USD
+1.65 (11.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.52 -0.03 (-0.18%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.55 USD
+1.65 (11.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.52 -0.03 (-0.18%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum C VGM
Zacks News
Thermo Fisher (TMO) Adds New Platform to CTS Product Portfolio
by Zacks Equity Research
Thermo Fisher (TMO) launches the next-generation Gibco CTS Detachable Dynabeads platform.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR), backed by the performance of the CALID and NANO groups and strength in acquisitions.
Exact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs
by Zacks Equity Research
Exact Sciences (EXAS) is improving customer experience by making it simpler to order Cologuard electronically and continue re-screening of patients every three years.
Align Technologies (ALGN) Set to Acquire Cubicure GmbH
by Zacks Equity Research
Align Technologies (ALGN) announces acquisition of direct 3D printing pioneer Cubicure GmbH, backed by years of successful collaboration.
Boston Scientific (BSX) WATCHMAN FLX Pro Gets FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) latest device features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS), backed by Cologuard growth and upbeat guidance.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on the RMS segment's continued growth and upbeat guidance.
Abbott (ABT) to Advance Diabetes Care With New Acquisition
by Zacks Equity Research
Abbott's (ABT) recent deal will enable it to create more interconnected solutions to improve the personalization and accuracy of diabetes control.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL), owing to the strong prospect of the advanced services portfolio.
Does Si-Bone (SIBN) Have the Potential to Rally 39.93% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 39.9% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
by Zacks Equity Research
Haemonetics' (HAE) share price is likely to grow, backed by solid business performance across all its segments.
Charles River (CRL) Gains From Global Demand Amid FX Woes
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on growth in the legacy business and upbeat guidance.
Zimmer Biomet (ZBH) Business Recovery Continues Despite FX Woe
by Zacks Equity Research
Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters.
LivaNova (LIVN) Advances Cardiopulmonary Wing With Essenz ILBM
by Zacks Equity Research
LivaNova's (LIVN) Essenz ILBM boasts B-Capta sensing technology, ensuring accuracy and compliance with Clinical Laboratory Improvement Amendments.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
A diversified product portfolio and a broad geographic footprint bode well for Teleflex (TFX).
Globus Medical (GMED) Completes NuVasive Merger Agreement
by Zacks Equity Research
Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most comprehensive, innovative offerings.
ICU Medical's (ICUI) Plum Duo With Safety Shield Gets 510(k) Nod
by Zacks Equity Research
The Plum Duo infusion pump represents the latest addition to ICU Medical's (ICUI) advanced lineup of infusion devices.
Neogen (NEOG) Launches SureKill Evolve SC Pest Management Tool
by Zacks Equity Research
Neogen (NEOG) introduces the latest solution in the SureKill brand of products, SureKill Evolve SC.
Boston Scientific's (BSX) FARAPULSE System Study Data Positive
by Zacks Equity Research
Boston Scientific's (BSX) FARAPULSE PFA System's performance in the trial is an encouraging sign of the potential utilization of the device in the United States.
Walgreens (WBA) OTC NARCAN Nasal Spray to be Available Soon
by Zacks Equity Research
Walgreens (WBA) is instructing Americans to administer this life-saving drug that, if given in time, can reverse the effects of an opioid overdose.
Abbott's (ABT) Libre Gains Momentum Amid Low Testing Sales
by Zacks Equity Research
Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.
Inspira (IINN) Advances Foothold in Europe With Extended Deal
by Zacks Equity Research
The extended service agreement complements a previously announced strategic agreement between Inspira (IINN) and Innovimed.
Here's Why You Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Integra (IART) based on the prospects of its CSS segment and a stable liquidity position.
Exact Sciences' (EXAS) OncoExtra Test Selected for ComboMATCH
by Zacks Equity Research
Exact Sciences' (EXAS) Laboratory and OncoExtra test gets selected by the NCI for ComboMATCH trials.